InstalabLoading...
InstalabLoading...
Your gut hosts trillions of bacteria, and most of them belong to one of two big families. Firmicutes is one of those families. The proportion of Firmicutes in your stool, often compared to a related family called Bacteroidetes, is a window into how your gut community is built and how it might be shaping your weight, blood sugar, mood, and inflammation.
This is a research-grade measurement, not a settled clinical test. Levels swing widely between healthy people, and the same number can mean different things in different bodies. The value comes from pairing it with the rest of your gut profile and tracking how it shifts when you change your diet, your medications, or your routine.
Firmicutes are a phylum (a broad biological grouping) of gut bacteria that includes many of your most important fiber-fermenting microbes. When you eat fiber, certain Firmicutes break it down into short-chain fatty acids (small molecules your colon uses for fuel and that help regulate inflammation, blood sugar, and the gut barrier). Some Firmicutes species, including Lactobacillus, are also used as probiotics.
Many discussions of Firmicutes use a comparison called the Firmicutes/Bacteroidetes (F/B) ratio. The idea is that the balance between these two big bacterial groups says something about energy extraction, inflammation, and metabolic health. The ratio is widely cited, but as you will see below, it is not a reliable standalone marker of any single condition.
This is the most studied area, and also the most contradictory. Some studies in obese adults find higher Firmicutes and a higher F/B ratio than in lean adults. In overweight and obese Italian adults, Firmicutes were enriched and positively correlated with body fat and negatively with muscle mass and physical activity. In Mexican women with obesity plus metabolic syndrome, the F/B ratio averaged 0.64 compared to 0.27 in healthier obese counterparts.
Other studies show no link, or even the opposite pattern. A systematic review and meta-analysis of obese versus non-obese adults found that differences in Firmicutes were modest and inconsistent across studies. A Croatian follow-up study concluded that the F/B ratio did not predict excess body weight, although weight gain over time was associated with a higher average ratio. A broad review of the field reported Firmicutes ranging from 11% to 95% of fecal bacteria across healthy individuals, making any universal cutpoint impossible.
What this means for you: a single Firmicutes reading should not be treated as a diagnosis of metabolic dysfunction. It is one input among many, useful mainly when interpreted alongside your weight trajectory, fasting insulin, lipids, and the rest of your gut profile.
In a study of adults with type 2 diabetes, Firmicutes were lower and the Bacteroidetes-to-Firmicutes ratio was higher compared to non-diabetic adults. A systematic review covering type 2 diabetes patients found that the F/B ratio varied with clinical parameters including blood glucose and lean tissue index. In gestational diabetes, decreased Firmicutes alongside increased Bacteroidetes has been linked to insulin resistance and metabolic syndrome features.
The direction of change is not consistent across all metabolic conditions, which is why this marker is best used as part of a broader picture rather than a yes-or-no test for diabetes risk.
In non-alcoholic fatty liver disease (NAFLD), one study used an F/B ratio of 1.09 or higher as part of the definition of dysbiosis (an unhealthy shift in the gut community), and the ratio correlated with liver fat in obese patients. In chronic liver disease and hepatocellular carcinoma, a pilot study found Firmicutes and a beneficial Firmicutes member called Blautia were markedly reduced, and the changes correlated with cirrhosis severity and unfavorable lab results.
A study of young adults with major depressive disorder found reductions in anti-inflammatory gut bacteria, including butyrate-producing Firmicutes such as Faecalibacterium and Ruminococcaceae. A separate analysis identified lower Firmicutes in depressed patients and tied it to low-grade inflammation. A systematic review and meta-analysis of depression and the gut microbiome found, at the broad phylum level, no consistent Firmicutes difference between depressed and healthy people, but did show shifts in specific Firmicutes genera.
The takeaway is the same pattern you will see throughout this biomarker: phylum-level numbers tell part of the story, but the specific genera within Firmicutes, and the people they live in, matter as much as the headline value.
Reading the literature, you will see higher Firmicutes linked to obesity in some studies and lower Firmicutes linked to liver disease, breast cancer, and depression in others. This is not a paradox. Firmicutes is a huge phylum containing thousands of species with very different jobs. Some are pro-inflammatory, some are anti-inflammatory, some make butyrate, some break down bile acids. A single phylum-level number averages over all of them. Two people with identical Firmicutes percentages can have entirely different gut ecosystems. That is why this marker is best treated as a broad ecological readout rather than a verdict on health.
There are no consensus clinical cutpoints for Firmicutes or the F/B ratio. The ranges below come from research cohorts of mostly healthy adults and are illustrative orientation only. Different labs use different sequencing methods and different reference databases, and your numbers will not translate directly between them.
| Population | Reported Range | What It Suggests |
|---|---|---|
| Healthy adults across multiple cohorts | Firmicutes 11% to 95% of fecal bacteria | The 'normal' span is enormous, and a single value cannot diagnose dysbiosis |
| Healthy young Chilean adults | Firmicutes 25% to 67% | A narrower band typical of homogeneous, healthy populations |
| NAFLD research definition | F/B ratio 1.09 or higher | Used as one criterion for gut dysbiosis in liver disease, not a clinical threshold |
Sources: Magne et al. 2020 (review); Fujio-Vejar et al. 2017 (Chilean cohort); Jasirwan et al. 2020 (NAFLD). Compare your results within the same lab over time, since absolute numbers shift with the assay used.
A single Firmicutes reading is a snapshot of an ecosystem that changes daily. Stool composition shifts with what you ate yesterday, how you slept, whether you traveled, and whether you took any medication recently. The signal worth paying attention to is the trend in the same lab using the same method.
If you are making a deliberate change such as adding more fiber, starting or stopping a medication, or following a Mediterranean-style eating pattern, it is reasonable to retest in 3 to 6 months and look at how your gut profile shifts. Beyond that, an annual check is enough to catch drift if you are otherwise stable. Track Firmicutes alongside Bacteroidetes, the F/B ratio, and the specific genera your panel reports, not in isolation.
Because there is no validated treatment threshold for Firmicutes, an out-of-range result is best treated as an invitation to look harder, not a diagnosis. Pair the result with your symptoms, your weight and waist trajectory, your fasting insulin, your hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker), and your liver enzymes.
If you are noticing GI symptoms such as bloating, irregular stools, or unexplained fatigue alongside an unusual Firmicutes pattern, a more detailed stool panel that reports specific genera, short-chain fatty acid output, calprotectin (a marker of gut inflammation), and pathogen testing will be more actionable than the phylum number alone. A gastroenterologist or a clinician comfortable with microbiome data is the right person to involve if the picture stays unclear.
Evidence-backed interventions that affect your Firmicutes level
Firmicutes is best interpreted alongside these tests.